FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:999-1008 March 6, 2008 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Shurin, S. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear.

Methods In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes (CYP2C9 *1, *2, and *3), VKORC1 haplotypes (designated A and non-A), clinical characteristics, response to therapy (as determined by the international normalized ratio [INR]), and bleeding events. The study outcomes were the time to the first INR within the therapeutic range, the time to the first INR of more than 4, the time above the therapeutic INR range, the INR response over time, and the warfarin dose requirement.

Results As compared with patients with the non-A/non-A haplotype, patients with the A/A haplotype of VKORC1 had a decreased time to the first INR within the therapeutic range (P=0.02) and to the first INR of more than 4 (P=0.003). In contrast, the CYP2C9 genotype was not a significant predictor of the time to the first INR within the therapeutic range (P=0.57) but was a significant predictor of the time to the first INR of more than 4 (P=0.03). Both the CYP2C9 genotype and VKORC1 haplotype had a significant influence on the required warfarin dose after the first 2 weeks of therapy.

Conclusions Initial variability in the INR response to warfarin was more strongly associated with genetic variability in the pharmacologic target of warfarin, VKORC1, than with CYP2C9.

Source Information

From the Departments of Medicine and Pharmacology (U.I.S., A.F.-A., R.B.K., D.M.R., C.M.S.), the Department of Molecular Physiology and Biophysics and the Center for Human Genetics Research (M.D.R., Y.B., S.M.D.), and the Department of Biostatistics (C.L.), Vanderbilt University School of Medicine, Nashville.

Full Text of this Article

Related Letters:

Genetics of Warfarin Response
Schillinger D., Neville K. A., Wicklund B. M., Kearns G. L., Kulkarni U. P., Karnad D. R., Gogtay N. J., Mannucci P. M., Spreafico M., Peyvandi F., Stein C. M., Roden D. M., Schwarz U. I.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2741-2744, Jun 19, 2008. Correspondence

This article has been cited by other articles:

• Meschia, J. F. (2009). Pharmacogenetics and Stroke. Stroke 40: 3641-3645 [Abstract] [Full Text]  
• Marin, F., Gonzalez-Conejero, R., Capranzano, P., Bass, T. A., Roldan, V., Angiolillo, D. J. (2009). Pharmacogenetics in cardiovascular antithrombotic therapy.. J Am Coll Cardiol 54: 1041-1057 [Abstract] [Full Text]  
• Patrick, A. R., Avorn, J., Choudhry, N. K. (2009). Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2: 429-436 [Abstract] [Full Text]  
• Hogan, K. J., Burmester, J. K., Caldwell, M. D., Hogan, Q. H., Coursin, D. B., Green, D. N., Selzer, R. M.R., Broderick, T. P., Rusy, D. A., Poroli, M., Lutz, A. L., Sanders, A. M., Oldenburg, M. C., Koelbl, J. A., de Arruda-Indig, M., Halsey, J. L., Day, S. P., Domanico, M. J. (2009). Perioperative Genomic Profiles Using Structure-Specific Oligonucleotide Probes. Clin Med Res 7: 69-84 [Abstract] [Full Text]  
• Bhatt, D. L. (2009). Tailoring Antiplatelet Therapy Based on Pharmacogenomics: How Well Do the Data Fit?. JAMA 302: 896-897 [Full Text]  
• Rosove, M. H., Grody, W. W. (2009). Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now. ANN INTERN MED 151: 270-273 [Abstract] [Full Text]  
• Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., Israel, C. W., Kuck, K.-H., Lip, G. Y.H., Nattel, S., Page, R. L., Ravens, U., Schotten, U., Steinbeck, G., Vardas, P., Waldo, A., Wegscheider, K., Willems, S., Breithardt, G. (2009). Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11: 860-885 [Full Text]  
• Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., John Camm, A., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., Israel, C. W., Kuck, K.-H., Lip, G. Y.H., Nattel, S., Page, R. L., Ravens, U., Schotten, U., Steinbeck, G., Vardas, P., Waldo, A., Wegscheider, K., Willems, S., Breithardt, G. (2009). Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 0: ehp235v1-ehp235 [Abstract] [Full Text]  
• Garcia, D. A., Hylek, E., Shil, A. B., Strohm, M. P., Klein, T. E., Kimmel, S. E., Johnson, J. A. (2009). Warfarin pharmacogenetics.. NEJM 360: 2474-2475 [Full Text]  
• Langley, M. R., Booker, J. K., Evans, J. P., McLeod, H. L., Weck, K. E. (2009). Validation of Clinical Testing for Warfarin Sensitivity: Comparison of CYP2C9-VKORC1 Genotyping Assays and Warfarin-Dosing Algorithms. J. Mol. Diagn. 11: 216-225 [Abstract] [Full Text]  
• Dichgans, M., Hegele, R. A. (2009). Update on the Genetics of Stroke and Cerebrovascular Disease 2008. Stroke 40: e289-e291 [Full Text]  
• Li, C., Schwarz, U. I., Ritchie, M. D., Roden, D. M., Stein, C. M., Kurnik, D. (2009). Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113: 3925-3930 [Abstract] [Full Text]  
• Yang, J. J., Cheng, C., Yang, W., Pei, D., Cao, X., Fan, Y., Pounds, S. B., Neale, G., Trevino, L. R., French, D., Campana, D., Downing, J. R., Evans, W. E., Pui, C.-H., Devidas, M., Bowman, W. P., Camitta, B. M., Willman, C. L., Davies, S. M., Borowitz, M. J., Carroll, W. L., Hunger, S. P., Relling, M. V. (2009). Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA 301: 393-403 [Abstract] [Full Text]  
• Ganz, P., Hsue, P. Y. (2009). Individualized approach to the management of coronary heart disease identifying the nonresponders before it is too late.. J Am Coll Cardiol 53: 331-333 [Full Text]  
• Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., Deloukas, P. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113: 784-792 [Abstract] [Full Text]  
• Eckman, M. H., Rosand, J., Greenberg, S. M., Gage, B. F. (2009). Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. ANN INTERN MED 150: 73-83 [Abstract] [Full Text]  
• Gulseth, M. P., Grice, G. R., Dager, W. E. (2009). Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 66: 123-133 [Abstract] [Full Text]  
• Nieuwlaat, R., Connolly, S. J (2009). Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. Heart 95: 95-97 [Full Text]  
• Hynicka, L. M, Cahoon, W. D Jr, Bukaveckas, B. L (2008). Genetic Testing for Warfarin Therapy Initiation. The Annals of Pharmacotherapy 42: 1298-1303 [Abstract] [Full Text]  
• Wang, D., Chen, H., Momary, K. M., Cavallari, L. H., Johnson, J. A., Sadee, W. (2008). Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112: 1013-1021 [Abstract] [Full Text]  
• Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., Veenstra, D. L., Rettie, A. E., Rieder, M. J. (2008). A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112: 1022-1027 [Abstract] [Full Text]  
• Januzzi, J. L. Jr (2008). Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter. Clin. Chem. 54: 1107-1109 [Full Text]  
• Schillinger, D., Neville, K. A., Wicklund, B. M., Kearns, G. L., Kulkarni, U. P., Karnad, D. R., Gogtay, N. J., Mannucci, P. M., Spreafico, M., Peyvandi, F., Stein, C. M., Roden, D. M., Schwarz, U. I. (2008). Genetics of Warfarin Response. NEJM 358: 2741-2744 [Full Text]  
• (2008). Warfarin Dose Modification by Genotyping. JWatch Oncology and Hematology 2008: 1-1 [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 336: 582-583 [Full Text]  
• Shurin, S. B., Nabel, E. G. (2008). Pharmacogenomics -- Ready for Prime Time?. NEJM 358: 1061-1063 [Full Text]  
• Bounameaux, H., Perrier, A. (2008). Duration of Anticoagulation Therapy for Venous Thromboembolism. ASH Education Book 2008: 252-258 [Abstract] [Full Text]  
• Francis, C. W. (2008). New Issues in Oral Anticoagulants. ASH Education Book 2008: 259-265 [Abstract] [Full Text]